^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TP53 mutation + PD-L1 expression

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
7ms
Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet (PubMed, Zhongguo Yi Xue Ke Xue Yuan Xue Bao)
Results The 64 patients with colorectal cancer were at a male-to-female ratio of 1.21∶1,with the mean age of (56.59±13.27) years.The tumors were located in the colon in 46(71.88%) patients and in the rectum in 18(28.12%) patients.Sixty(93.75%) patients presented adenocarcinoma,and 4(6.25%) patients presented other types of tumors.The patients in T1/T2 and T3/T4 phases accounted for 17.19%(n=11) and 82.81%(n=53),respectively.Lymph node metastasis occurred in 24(37.50%) patients.The immunohistochemical staining results showed partially down-regulated or absent expression of SMARCA4 in 1(1.56%) patient,positive BRAF expression in 4(6.25%) patients,and mutant expression of P53 in 35(54.69%) patients.The PD-1-expressing tumor associated immune cell was proportion score<10% in 45(70.31%) patients and≥10% in 19(29.69%) patients.The PD-L1 combined positive score was<10 in 52(81.25%) patients and≥10 in 12(18.75%) patients.The gene fusion of NTRK1,NTRK2,and NTRK3 was negative in all the patients,and BRAF V600E gene mutation was positive in 4(6.25%) patients.The SMARCA4 gene alteration was not detected in the patient with partial expression missing of SMARCA4.The PD-L1 combine positive score was correlated with the deficient mismatch repair(dMMR)/microsatellite instability-high (MSI-H) and the PD-1 expression (χ2=10.223,P=0.001;χ2=11.979,P=0.001). Conclusions The down-regulated or absent SMARCA4 expression and NTRK gene fusion are rare in the patients with colorectal cancer in Tibet.A few patients present BRAF V600E gene mutations,and Pan-TRK and BRAF expression can be used for the primary screening of NTRK gene fusion and BRAF gene mutation.The patients with dMMR/MSI-H are prone to high expression of PD-L1 and expected to benefit from immunotherapy.No significant correlation exists between P53 mutation and PD-L1 expression.The high expression of PD-1 is positively correlated with the high expression of PD-L1.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • PD-1 (Programmed cell death 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NTRK (Neurotrophic receptor tyrosine kinase) • SMARCD3 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3)
|
TP53 mutation • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • NTRK1 fusion • NTRK2 fusion • PD-1 expression • TP53 expression • BRAF positive • TP53 mutation + PD-L1 expression • NTRK expression • NTRK fusion
over1year
R-CHOP WITH SINTILIZUMAB IN FIRST-LINE TREATMENT OF LARGE B-CELL LYMPHOMA PATIENTS WITH TP53 MUTATIONS AND PD-L1 EXPRESSION: A RANDOMIZED, MULTICENTER CLINICAL STUDY (ICML 2023)
Although 60% of patients can be cured by standard R-CHOP (rituximab plus cyclophosphamide, doxoru bicin, vincristine, and prednisone) as frontline therapy, patients with resistance to primary chemoimmunotherapy have a poor prognosis...Afterwards, patients with TP53 mutations and PD-L1 expression (≥30% by IHC) are randomly assigned (1:1) to receive either sintilimab plus R-CHOP regimen (group A) or R-CHOP only (group B) for 5 cycles, until disease progression, unacceptable toxicity or withdrawal of consent...Safety was assessed in all treated patients. The study is registered with www.chictr.org, NCT05280626 and is ongoing.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
|
PD-L1 expression • TP53 mutation • TP53 mutation + PD-L1 expression
|
Rituxan (rituximab) • Tyvyt (sintilimab) • cyclophosphamide • vincristine
over1year
Genomic profiling and sites of metastasis in non-small cell lung cancer (NSCLC) (AACR 2023)
Metastatic lung cancer patients with discoverable mutations on NGS are more likely to have metastatic disease to the brain. PDL-1 expression and TP53 mutation tend to lead to disease metastatic to organs other than brain or bone. Patients with EGFR mutations, despite having a great propensity to brain metastasis, have significantly better PFS and OS than patients with KRAS/NRAS and TP53 mutations, likely due to targeted therapy options.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • NRAS mutation • TP53 expression • TP53 mutation + PD-L1 expression
almost2years
Impact of TP53/KRAS mutations on Overall Survival of Metastatic non-Small Cell Lung Cancer Patients (pts) Treated with Systemic First-line Therapy (ELCC 2023)
TP53 mutations could represent a potential biomarker for treatment selection for pts with low PDL1 expression treated with chemo-immunotherapy. Prospective validation is needed.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • TP53 mutation • KRAS mutation • TP53 mutation + KRAS mutation • PD-1-L • PD-L1-L • TP53 mutation + PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay • Oncomine Precision Assay